FDA Discusses Psychedelic Therapies and Patient Safety

The U.S. Food and Drug Administration convened a public hearing to address psychedelic treatments for severe mental illness. Discussions centered on ensuring patient safety and establishing a clear regulatory pathway for these emerging therapies. This engagement is vital for guiding the responsible development and potential integration of psychedelics into mental healthcare.